【摘 要】
：
Cancer treatment responses and late normal tissue injury are conventionally assessed months or years after the completion of therapy by standard clinical endpoints, such as local progression free surv
【机 构】
：
Department of Radiation Oncology and Radiology University of Michigan USA
【出 处】
：
BIT Life Sciences 1st Annual World Cancer Congess-2008(2008中
论文部分内容阅读
Cancer treatment responses and late normal tissue injury are conventionally assessed months or years after the completion of therapy by standard clinical endpoints, such as local progression free survival or late fibrosis.This conventional paradigm presents two major weaknesses.First, at the time by which tumor progression is identified, it is often too late to change the outcome of patients.Second, a large population of patients and extended followup times are required to determine the efficacy of the tested treatment.In addition, late determination of normal tissue toxicity limits or eliminates the time window available for therapeutic intervention to prevent or reduce normal tissue injury.Therefore, it is urgent for clinical scientists to change this conventional paradigm and to assess the therapeutic response and toxicity early, i.e.prior to the end ofplarmed therapy.For early assessment of therapeutic responses, conventional clinical endpoints are no longer adequate.
其他文献
The significant advances in microarray and proteomics analyses have resulted in an exponential increase in potential new targets and have promised to shed light on the identification of disease marker
The Drosophila dachshund (dac) gene is a helix-turn-helix nuclear protein that governs cell fate determination.Dac is essential for the development of the drosophila eye and limb.The dac gene forms pa
RECK is a membrane-anchored glycoprotein which may negatively regulate matrix metalloproteinase (MMP) activity to suppress tumor invasion and metastasis.In this study, recombinant proteins correspondi
Human ductal carcinoma in situ (DCIS) represents the earliest identifiable breast cancer lesion, in which tumor cells remain confined by the architecture of the duct, surrounded on all sides by myoepi
Dr.Collins will present on the use of array comparative genomic hybridization (aCGH) and end sequence profiling (ESP) for the development of novel biomarkers and therapeutic targets for cancer.Prostat
Introduction: Better prognostic and predictive tools are necessary for personalized treatment decisions in lymph node-negative, estrogen receptor-positive breast cancer patients.The 21-gene recurrence
Objective: Guidelines for breast health care (early detection, diagnosis and treatment) that were developed in high resource countries cannot be directly applied in limited resource countries (LRC), b
Osteonecrosis of the jaw (ON J) related with the use of potent bisphosphonates has been defined as the persistence of exposed bone in the oral cavity after adequate treatment for 8 weeks, in the absen
Magnetic resonance (MR) imaging-histology co-registration techniques in combination with the use of MR contrast agents have been established for in vivo characterization of rodent models of primary an
Background: Human epidermal growth factor receptor type 2 (HER2) overexpression is associated with accelerated disease progression and poor prognosis in breast cancer (1,2,3).Several studies have foun